PP
KYMR icon

PDT Partners’s Kymera Therapeutics KYMR Stock Holding History

PDT Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,546
Closed -$223K – 709
2024
Q1 		$223K Buy
+5,546
New +$198K 0.02% 567
2021
Q4 		– Sell
-5,265
Closed -$309K – 943
2021
Q3 		$309K Buy
+5,265
New +$305K 0.02% 588

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

PDT Partners's KYMR Position: Q2 2024 in Review

PDT Partners sold out of Kymera Therapeutics (KYMR) in Q2 2024, closing a stake of 5,546 shares — an estimated $223K sold.

PDT Partners first reported a position in KYMR in Q3 2021 and held it in 2 quarters. The position peaked at $309K in Q3 2021. 157 funds tracked by Wall St. Rank hold KYMR as of Q2 2024.

  • PDT Partners reported no remaining Kymera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • PDT Partners sold 5,546 Kymera Therapeutics shares in Q2 2024, an estimated $223K.
  • PDT Partners first reported a position in Kymera Therapeutics in Q3 2021 and held it in 2 quarters.
  • PDT Partners's Kymera Therapeutics position peaked at $309K in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2024.

Based on PDT Partners's 13F filing for Q2 2024, filed 15 Aug 2024.